Neoadjuvant androgen depletion in combination with vorinostat followed by radical prostatectomy for localized prostate cancer: total androgen-receptor gene expression targeted therapy (TARGET)

Trial Profile

Neoadjuvant androgen depletion in combination with vorinostat followed by radical prostatectomy for localized prostate cancer: total androgen-receptor gene expression targeted therapy (TARGET)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Bicalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Vorinostat (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TARGET
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 26 Jul 2013 Planned end date changed from 1 Jan 2100 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top